Tyr Pharma's stock surged on positive data for pulmonary sarcoidosis treatment, but cash balance risk keeps investors ...

Fintel reports that on January 6, 2025, Cantor Fitzgerald initiated coverage of aTyr Pharma (NasdaqCM:ATYR) with a Overweight ...

Cantor Fitzgerald initiated coverage of aTyr Pharma (ATYR) with an Overweight rating. aTyr Pharma’s lead drug Efzofitimod is in two trials for ...

Equities research analysts at Cantor Fitzgerald started coverage on shares of Atyr PHARMA (NASDAQ:ATYR – Get Free Report) in a research report issued to clients and investors on Monday,Briefing.com ...

aTyr Pharma, Inc. announced the appointment of Eric Benevich to its Board of Directors, effective December 10, 2024. Benevich, currently the Chief Commercial Officer at Neurocrine Biosciences ...

SAN DIEGO, Dec. 10, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of ...

If you want to know who really controls aTyr Pharma, Inc. (NASDAQ:ATYR), then you'll have to look at the makeup of its share registry. The group holding the most number of shares in the company ...

Atyr PHARMA (NASDAQ:ATYR – Get Free Report)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a note issued to investors on Tuesday,Benzinga reports.

Soumit Roy, an analyst from JonesTrading, maintained the Buy rating on aTyr Pharma (ATYR – Research Report). The associated price target remains the same with $22.00. Pick the best stocks and ...

SAN DIEGO, Dec. 10, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of ...